Fundraising Fox

CG Oncology

NASDAQ: CGON

Incorporated in Delaware Β· 6 known investors

cgoncology.com β†—

CG Oncology is a clinical-stage biotechnology company developing bladder-sparing oncolytic immunotherapies for patients with bladder cancer. Its lead investigational drug, cretostimogene, is an intravesically delivered immunotherapy being evaluated for non-muscle invasive bladder cancer (NMIBC).

BiotechHealthtech

Investors Β· 6

Decheng CapitalMenlo Park
Foresite CapitalLarkspur
Longitude CapitalMenlo Park Β· $10M – $30M
Palm Drive CapitalNew York Β· $500K – $5M
RA CapitalBoston
TCG CrossoverPalo Alto

Frequently asked questions

What does CG Oncology do?
CG Oncology is a clinical-stage biotechnology company developing bladder-sparing oncolytic immunotherapies for patients with bladder cancer. Its lead investigational drug, cretostimogene, is an intravesically delivered immunotherapy being evaluated for non-muscle invasive bladder cancer (NMIBC).
Who are CG Oncology's investors?
CG Oncology's investors include Decheng Capital, Foresite Capital, Longitude Capital, Palm Drive Capital, RA Capital, TCG Crossover.